These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29017927)

  • 1. Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na
    El-Bizri N; Xie C; Liu L; Limberis J; Krause M; Hirakawa R; Nguyen S; Tabuena DR; Belardinelli L; Kahlig KM
    Heart Rhythm; 2018 Feb; 15(2):277-286. PubMed ID: 29017927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ Na
    Alvarez-Collazo J; López-Requena A; Alvarez JL; Talavera K
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel late Na
    Rajamani S; Liu G; El-Bizri N; Guo D; Li C; Chen XL; Kahlig KM; Mollova N; Elzein E; Zablocki J; Belardinelli L
    Br J Pharmacol; 2016 Nov; 173(21):3088-3098. PubMed ID: 27449698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
    Fredj S; Sampson KJ; Liu H; Kass RS
    Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Potet F; Egecioglu DE; Burridge PW; George AL
    Mol Pharmacol; 2020 Nov; 98(5):540-547. PubMed ID: 32938719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
    Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
    Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed Ventricular Repolarization and Sodium Channel Current Modification in a Mouse Model of Rett Syndrome.
    Cheng H; Charles I; James AF; Abdala AP; Hancox JC
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
    Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
    Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of Ranolazine on E1784K is altered by temperature and calcium.
    Abdelsayed M; Ruprai M; Ruben PC
    Sci Rep; 2018 Feb; 8(1):3643. PubMed ID: 29483621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
    Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
    PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
    Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
    J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late Sodium Current in Atrial Cardiomyocytes Contributes to the Induced and Spontaneous Atrial Fibrillation in Rabbit Hearts.
    Chu Y; Yang Q; Ren L; Yu S; Liu Z; Chen Y; Wei X; Huang S; Song L; Zhang P; Ma J; Wu L
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):437-444. PubMed ID: 32675747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.
    Nasilli G; Yiangou L; Palandri C; Cerbai E; Davis RP; Verkerk AO; Casini S; Remme CA
    Europace; 2023 Jun; 25(6):. PubMed ID: 37369559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic effect of IKr activation in a cellular model of LQT3.
    Diness JG; Hansen RS; Nissen JD; Jespersen T; Grunnet M
    Heart Rhythm; 2009 Jan; 6(1):100-6. PubMed ID: 19121808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial-ventricular differences in rabbit cardiac voltage-gated Na
    Caves RE; Cheng H; Choisy SC; Gadeberg HC; Bryant SM; Hancox JC; James AF
    Heart Rhythm; 2017 Nov; 14(11):1657-1664. PubMed ID: 28610990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
    Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of voltage-gated Na
    Caves RE; Carpenter A; Choisy SC; Clennell B; Cheng H; McNiff C; Mann B; Milnes JT; Hancox JC; James AF
    Heart Rhythm O2; 2020 Aug; 1(3):206-214. PubMed ID: 32864638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent adrenergic stimulation.
    Justo F; Fuller H; Nearing BD; Rajamani S; Belardinelli L; Verrier RL
    Heart Rhythm; 2016 Sep; 13(9):1860-7. PubMed ID: 27317981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.